-

Angel Reyes Joins Altasciences as General Manager of CDMO Services

LAVAL, Québec--(BUSINESS WIRE)--Altasciences is pleased to welcome Angel Reyes as General Manager, Contract Development and Manufacturing Organization (CDMO) Services.

Angel joins Altasciences having previously been the Director of Operations at Catalent. He brings to Altasciences over a decade of experience in management and supervisory roles for manufacturing operations and supply chains, having demonstrated an impeccable standard in ensuring adherence to compliance and cGMP policies.

Angel graduated with a bachelor’s degree in chemistry from the University of Eastern Kentucky and began his career as an analyst before stepping into the role of Pharmaceutical Scientist, where he was responsible for the manufacturing and preparation of commercial solid dosage forms.

Angel’s scientific knowledge and wealth of experience gained over years in managing manufacturing operations, combined with his ability to find innovative solutions and improve day-to-day operations, makes him a valuable addition to the CDMO team. I am confident he will have a significant impact on the organization,” said Ben Reed, Executive General Manager, CDMO Services, Altasciences.

As General Manager, Angel is responsible for overseeing day-to-day operations in analytical and manufacturing services and managing client relations.

About Altasciences

Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster. To learn more about Altasciences, visit altasciences.com.

Contacts

Julie-Ann Cabana
Altasciences
+1 514 601-9763
jcabana@altasciences.com

Altasciences

Details
Headquarters: Laval, Canada
CEO: Chris Perkin
Employees: 2,000+
Organization: PRI


Contacts

Julie-Ann Cabana
Altasciences
+1 514 601-9763
jcabana@altasciences.com

Social Media Profiles
More News From Altasciences

Altasciences and Evidence Matters Advance AI-Driven Drug Development With Nonclinical Automation Breakthrough

LAVAL, Québec--(BUSINESS WIRE)--Altasciences, a fully integrated early-phase drug development organization, and Evidence Matters, a pioneer in clinical trial data science, are pleased to announce a successful proof-of-concept (POC) of RegulatoryFlow (“RegFlow”), following the announcement of the companies’ strategic collaboration in August 2025. The POC demonstrated the extension of AI-driven efficiencies from clinical reporting into nonclinical workflows, marking a significant step forward in...

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™

LAVAL, Québec--(BUSINESS WIRE)--Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Thera...

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development

LAVAL, Québec & RADNOR, Pa.--(BUSINESS WIRE)--Altasciences, a fully integrated drug development solution company, and Certara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals...
Back to Newsroom